Evidence map›Paper›PMID 37930837›Full record

ArticleNucleic acids research2024

INTEDE 2.0: the metabolic roadmap of drugs.

Yang Zhang, Xingang Liu, Fengcheng Li, Jiayi Yin, Hao Yang, Xuedong Li, Xinyu Liu, Xu Chai, Tianle Niu, Su Zeng and 2 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning.Database : the journal of biological databases and curation · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yang ZhangSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Xingang LiuSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Fengcheng LiCollege of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Jiayi YinCollege of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Hao YangSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Xuedong LiSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Xinyu LiuSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Xu ChaiSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Tianle NiuSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Su ZengCollege of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0002-1418-6825
Qingzhong JiaSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Feng ZhuSchool of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.ORCID 0000-0001-8069-0053

Funding

Alibaba-Zhejiang University Joint Research Center of Future Digital HealthcareFundamental Research Funds for Central Universities 2018QNA7023Hebei Provincial Department of Science and Technology 21372601DInformation Technology Center of Zhejiang UniversityKey R&D Program of Zhejiang Province 2020C03010Leading Talent of the 'Ten Thousand Plan' National High-Level Talents Special Support Plan of ChinaNational Key R&D Program of China 2022YFC3400501National Natural Science Foundation of China 82373790Natural Science Foundation of Hebei Province H2021206448Natural Science Foundation of Zhejiang Province LR21H300001The Double Top-Class Universities 181201*194232101Westlake Laboratory (Westlake Laboratory of Life Science & Biomedicine); Alibaba Cloud
6 · The paper itself

Abstract

The metabolic roadmap of drugs (MRD) is a comprehensive atlas for understanding the stepwise and sequential metabolism of certain drug in living organisms. It plays a vital role in lead optimization, personalized medication, and ADMET research. The MRD consists of three main components: (i) the sequential catalyses of drug and its metabolites by different drug-metabolizing enzymes (DMEs), (ii) a comprehensive collection of metabolic reactions along the entire MRD and (iii) a systematic description on efficacy & toxicity for all metabolites of a studied drug. However, there is no database available for describing the comprehensive metabolic roadmaps of drugs. Therefore, in this study, a major update of INTEDE was conducted, which provided the stepwise & sequential metabolic roadmaps for a total of 4701 drugs, and a total of 22 165 metabolic reactions containing 1088 DMEs and 18 882 drug metabolites. Additionally, the INTEDE 2.0 labeled the pharmacological properties (pharmacological activity or toxicity) of metabolites and provided their structural information. Furthermore, 3717 drug metabolism relationships were supplemented (from 7338 to 11 055). All in all, INTEDE 2.0 is highly expected to attract broad interests from related research community and serve as an essential supplement to existing pharmaceutical/biological/chemical databases. INTEDE 2.0 can now be accessible freely without any login requirement at: http://idrblab.org/intede/.

Indexed as

Databases, ChemicalDatabases, FactualImidazolesInactivation, MetabolicOrganosilicon CompoundsPharmaceutical PreparationsdimethylethylsilylimidazoleImidazolesOrganosilicon CompoundsPharmaceutical Preparations

Identifiers

PMID37930837
PMCPMC10767827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.